Ocuphire Pharma, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Stockholders' Equity, At-The-Market Program (Details)

Stockholders' Equity, At-The-Market Program (Details) - USD ($)			3 Months Ended		6 Months Ended		40 Months Ended
	Mar. 11, 2021	Feb. 12, 2021	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024
At-The-Market Program [Abstract]
Proceeds from issuance of common stock in connection with the at-the-market program and purchase agreement					$ 4,041,000	$ 0
Issuance costs					$ 83,000	$ 0
2021 Shelf [Member] \| Maximum [Member]
At-The-Market Program [Abstract]
Aggregate offering price		$ 125,000,000
ATM [Member]
At-The-Market Program [Abstract]
Shares sold (in shares)			538,566	0	1,389,116	0	7,434,432
Proceeds from issuance of common stock in connection with the at-the-market program and purchase agreement			$ 1,100,000		$ 3,300,000		$ 26,000,000
Issuance costs			$ 25,000		$ 190,000		$ 900,000
ATM [Member] \| Maximum [Member]
At-The-Market Program [Abstract]
Aggregate offering price	$ 40,000,000

Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.

+ References + Details